{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "esgPopulated": false, "market": "dr_market", "longName": "ValiRx plc", "marketState": "REGULAR", "regularMarketPrice": 0.11, "messageBoardId": "finmb_28075629", "exchange": "FRA", "shortName": "VALIRX PLC  LS-,001", "exchangeTimezoneShortName": "CEST", "exchangeTimezoneName": "Europe/Berlin", "regularMarketChangePercent": 0.0, "gmtOffSetMilliseconds": 7200000, "fiftyTwoWeekLowChange": 0.013999999, "fiftyTwoWeekLowChangePercent": 0.14583331, "fiftyTwoWeekRange": "0.096 - 0.34", "fiftyTwoWeekHighChange": -0.23, "fiftyTwoWeekHighChangePercent": -0.6764706, "fiftyTwoWeekLow": 0.096, "fiftyTwoWeekHigh": 0.34, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.03, "firstTradeDateMilliseconds": 1531893600000, "priceHint": 4, "regularMarketChange": 0.0, "regularMarketTime": 1683880220, "regularMarketDayHigh": 0.11, "regularMarketDayRange": "0.11 - 0.11", "regularMarketDayLow": 0.11, "regularMarketVolume": 2270, "regularMarketPreviousClose": 0.11, "bid": 0.11, "ask": 0.129, "fullExchangeName": "Frankfurt", "financialCurrency": "GBP", "regularMarketOpen": 0.11, "averageDailyVolume3Month": 38, "averageDailyVolume10Day": 0, "sharesOutstanding": 102320000, "bookValue": 0.044, "fiftyDayAverage": 0.11104, "fiftyDayAverageChange": -0.0010400042, "fiftyDayAverageChangePercent": -0.009366032, "twoHundredDayAverage": 0.142155, "twoHundredDayAverageChange": -0.032155007, "twoHundredDayAverageChangePercent": -0.2261968, "marketCap": 11326480, "priceToBook": 2.5, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "symbol": "EAJF.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Stonebridge House", "address2": "Chelmsford Road", "city": "Hatfield", "zip": "CM22 7BD", "country": "United Kingdom", "website": "https://www.valirx.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of women with endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Hatfield, the United Kingdom.", "fullTimeEmployees": 7, "companyOfficers": [{"maxAge": 1, "name": "Dr. Suzanne J. Dilly B.Sc., BSc, Ph.D.", "age": 44, "title": "CEO & Director", "yearBorn": 1978, "fiscalYear": 2021, "totalPay": {"raw": 200968, "fmt": "200.97k", "longFmt": "200,968"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. James Gerry Desler FCA", "age": 66, "title": "CFO & Exec. Director", "yearBorn": 1956, "fiscalYear": 2021, "totalPay": {"raw": 60600, "fmt": "60.6k", "longFmt": "60,600"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Kumar  Nawani", "title": "Head of Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Catherine Jane Tralau-Stewart Ph.D.", "title": "Chief Scientific Officer & Board Observer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Tarquin  Edwards", "title": "Head of Investor Relations & Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Mark  Treharne", "title": "Corp. Devel. Mang.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1640908800, "maxAge": 86400}}], "error": null}}